Skip to content

Remedy Robotics develops an AI-powered robotic system for endovascular interventions, aiming to address access and precision challenges in treating cardiovascular diseases like stroke and bleeding.

Public-source profile · Company ownership not verified. Sources & corrections

The short feature · 1 min read

Remedy Robotics, at a glance

Company-sourced feature

Built for · Hospitals, neurointerventional clinicians, and healthcare systems seeking to improve access to endovascular treatments for stroke and bleeding patients.

Based on company material. Product claims are attributed to the company.

  1. 01

    The problem

    Cardiovascular diseases—including stroke, heart attack, and bleeding—cause more deaths and disabilities than all cancers combined. Endovascular intervention is the gold-standard treatment, but fewer than 3% of eligible stroke patients globally receive it in time due to limited access, slow procedures, and human error risks.

    Sources [1]

  2. 02

    The product approach

    Remedy Robotics’ N1 System is a robotic platform designed for fully robotic, end-to-end endovascular procedures. It combines AI-driven tool control, 3D visualization, and teleoperation to enable precise interventions from remote locations, reducing reliance on local expertise and speeding up treatment delivery.

    Sources [1]

  3. 03

    What stands out

    Unlike traditional manual or semi-automated systems, the N1 System is the first to enable *entirely* robotic neurointerventional procedures, including remote control. Clinical milestones include the world’s first fully robotic and remotely controlled neurointerventional cases, demonstrating its capability to replicate expert-level precision without physical presence.

    Sources [1]

What could be hard to replicate?

A useful product is not automatically a moat. These mechanisms need evidence of a lasting advantage.

  • Technology & IP

    Company claim

    The N1 System’s integration of AI-native visualization and ML-based tool control creates a proprietary workflow that reduces procedural variability and improves precision. This is supported by Remedy’s clinical milestones in fully robotic and remote interventions, which suggest a unique capability to standardize complex procedures.

    Mechanism → evidence check

    What prevents another team from reproducing the capability?

    Sources [1]

The question to watch

How will Remedy Robotics’ system compare in real-world adoption to existing semi-automated or manual endovascular tools, particularly in terms of procedural success rates, clinician training requirements, and cost-effectiveness?

Explore the evidence · 1 source
  1. [1] Remedy Robotics company website

    Company material · checked 17/11/2026

    Led by DCVC, with UC Investments, Blackbird, Skip and others. Working with leading hospitals and clinicians The Problem Cardiovascular diseases like stroke, heart attack, and…

About

AI-powered endovascular intervention for every patient, everywhere.

Founders

  • a doctor and surgical robotics PhD
Profile sources, ownership & corrections

Company ownership is not verified

This profile was compiled from public sources and hasn't been verified by Remedy Robotics. Claim it to correct the details, add your team and funding history, and request review of your company information.

Compiled from news coverage, the company's own website.

ShareLinkedInXWhatsApp

Similar startups

Boltz is an AI-driven platform specializing in biomolecular design for drug discovery.

Disseqt offers an AI Assurance Platform designed to address governance challenges in enterprise AI operations.

Stoa provides a toolkit for AI-assisted software development by offering pre-built templates, security defaults.

Fermat is an AI-powered toolbox designed to accelerate fashion design workflows for retail and consumer packaged goods (CPG) teams.